Showing 1 - 7 of 7 Urinary Tract, Sexual Organs, and Pregnancy Conditions

Status: Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

The study evaluates the response to treatment with Ribociclib and Letrozole in patients with recurrent low grade serous cancer of the ovary, fallopian tube or peritoneum. ... Read more >

Status: Open Not Enrolling

Investigator: Raj Satkunasivam

Study Coordinator: Taliah Muhammad

Phone: 346.238.4523

This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder ... Read more >

Status: Enrolling

Investigator: Tarrik Zaid

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. ... Read more >

Status: Open Not Enrolling

Investigator: Eleni Efstathiou

Study Coordinator:

Phone:

This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolle ... Read more >

Status: Enrolling

Investigator: Eleni Efstathiou

Study Coordinator:

Phone:

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. ... Read more >

Status: Open Not Enrolling

Investigator: Kirk Heyne

Study Coordinator:

Phone:

This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced uro ... Read more >